The 9 linked references in paper Roman Shakhnovich M., Р. Шахнович М. (2018) “РАННЕЕ НАЗНАЧЕНИЕ ИНГИБИТОРОВ P2Y12-РЕЦЕПТОРОВ ТРОМБОЦИТОВ БОЛЬНЫМ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ: ПОЛЬЗА ИЛИ ВРЕД? // EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?” / spz:neicon:aterotromboz:y:2018:i:2:p:76-86

  1. Di sciascio G., Patti G., Pasceri V., Gatto L., Colonna G., Montinaro A. ARMYDA-5 PReLoAD. effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PReLoAD (Antiplatelet therapy for острый коронарный синдром Reduction of MYocardial Damage during Angioplasty) Investigators. J Am Coll Cardiol. 2010 Aug 10; 56(7): 550–557. doi: 10.1016/j.jacc.2010.01.067.
  2. Koul s., smith J.G., scherste ́n F., James s., Lagerqvist B., erlinge D. effect of upstream clopidogrel treatment in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal. 2011; 32: 2989–2997, doi: 10.1093/eurheartj/ehr202.
  3. Bellemain-Appaix A., o’Connor s.A., silvain J. et al. for the ACtIon group. Association of Clopidogrel Pretreatment With Mortality, Cardiovascular events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary InterventionA systematic Review and Meta-analysis. JAmA. 2012; 308(23): 2507–2516. doi: 10.1001/jama.2012.50788.
  4. Bagai A., Goodman s.G., Cantor W.J., Vicaut e., Bolognese L., Cequier A., Chettibi M., Hammett C.J., Huber K., Janzon M., Lapostolle F., Lassen J.F., Merkely B., storey R.F., ten Berg J.M., Zeymer U., Diallo A., Hamm C.W., tsatsaris A., el Khoury J., Van’t Hof A.W. Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with st -segment elevation myocardial infarction: Insights from the AtLAntIC study. Montalescot G. Am Heart J. 2018 Feb; 196: 56–64. doi: 10.1016/j.ahj.2017.10.021. epub 2017 nov 4.
  5. Venetsanos D., sederholm Lawesson s., Alfredsson J., Janzon M., Cequier A., Chettibi M., Goodman s.G., Van’t Hof A.W., Montalescot G., swahn e. Association between gender and short-term outcome in patients with st elevation myocardial infraction participating in the international, prospective, randomised Administration of ticagrelor in the catheterisation Laboratory or in the Ambulance for new st elevation myocardial Infarction to open the Coronary artery (AtLAntIC) trial: a prespecified analysis. BmJ Open. 2017 sep 21; 7(9): e015241. doi: 10.1136/bmjopen-2016-015241.
  6. Collet J.P., Kerneis M., Lattuca B., Yan Y., Cayla G., silvain J., Lapostolle F., ecollan P., Diallo A., Vicaut e., Hamm C.W., Van ‘t Hof A.W., Montalescot G. the effect of prehospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for st-segment elevation myocardial infarction: the AtLAntIC-elderly analysis. Euro Intervention. 2018 Jul 3; pii: eIJ-D-1800182. doi: 10.4244/eIJ-D-18-00182.
  7. Koul s., smith J.G., Götberg M., omerovic e., Alfredsson J., Venetsanos D., Persson J., Jensen J., Lagerqvist B., Redfors B., James s., erlinge D. no Benefit of ticagrelor Pretreatment Compared With treatment During Percutaneous Coronary Intervention in Patients With st-segmentelevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2018 Mar; 11(3): e005528. doi: 10.1161/ CIRCInteRVentIons.117.005528.
  8. Montalescot G., Bolognese L., Dudek D., Goldstein P., Hamm C., tanguay J.F., ten Berg J.M., Miller D.L., Costigan t.M., Goedicke J., silvain J., Angioli P., Legutko J., niethammer M., Motovska Z., Jakubowski J.A., Cayla G., Visconti L.o., Vicaut e., Widimsky P. ACCoAst Investigators. Pretreatment with prasugrel in non-st-segment elevation acute coronary syndromes. n Engl J med. 2013 sep 12; 369(11): 999– 1010. doi: 10.1056/neJMoa1308075. epub 2013 sep 1.
  9. Lemesle G., Laine M., Pankert M., Puymirat e., Cuisset t., Boueri Z., Maillard L., Armero s., Cayla G., Bali L., Motreff P., Peyre J.P., Paganelli F., Kerbaul F., Roch A., Michelet P., Baumstarck K., Bonello L. early versus delayed invasive strategy for intermediate- and highrisk acute coronary syndromes managed without P2Y12 receptor inhibitor pretreatment: Design and rationale of the eARLY randomized trial. Clin Cardiol. 2018 Jan; 41(1): 5-12. doi: 10.1002/clc.22852. epub 2018 Jan 22.